Clinical leader brings deep expertise in clinical development, medical and regulatory affairs Newton, MA, June 2, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells today … Read More
Author Archives: abcuro
Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer
Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline Newton, MA, January 7, 2021– Abcuro, Inc., a … Read More
Abcuro Granted Orphan Drug Designation for ABC008 for Inclusion Body Myositis
Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that … Read More
Abcuro Founder Reports on the Role of KLRG1+ T cells in Inclusion Body Myositis
Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More
Abcuro Founder Reports on the Role of KLRG1+ T cells in Primary Billiary Cholangitis
Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More
National Cancer Institute Awards SBIR Grant to Advance Development of KLRG1 Targeted Therapy for Melanoma
Abcuro Inc., announced that it has been awarded a Small Business Innovation Research Grant (SBIR) from the NIH National Cancer Institute. This Phase I grant will support advancement of the company’s anti-KLRG1 blocking antibody (ABC-015) with support for testing in … Read More
ProBioGen and Abcuro sign GlymaxX®-Improved Cell Line Development and GMP Production Agreement
Berlin, Germany, May 23rd, 2019 ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, … Read More
Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target KLRG1…
Antibody blockade induces anticancer response in solid tumor models. First in vivo validation of KLRG1 as a cancer immunotherapy target. KLRG1 is a driver of adaptive resistance to immunotherapy in humans. NEWTON, Mass., March 26, 2019 /PRNewswire/ — Abcuro, Inc., a biopharmaceutical … Read More
ABCURO ANNOUNCES $8M SERIES A FINANCING
This financing will advance the preclinical development of their programs in autoimmunity and immuno-oncology. Cambridge, MA – Abcuro, a leading biotechnology company focused on immunology therapeutics, announced the completion of a $8M Series A financing round. Partners Innovation Fund, Kaitai … Read More
Tags: Shortcodes